Express Scripts knocks many newer brands off formulary

Share this article:

Express Scripts, the big PBM, issued its new formulary for 2014, and a list accompanying the formulary shows many recently approved brands won't be covered, reports FiercePharma. Among those being excluded from reimbursement: Pfizer RA drug Xeljanz, Johnson & Johnson psoriasis treatment Stelara, and  GlaxoSmithKline respiratory drug Breo Ellipta. Alternatives are listed beside each.

It's the first time the PBM's preferred formulary designates certain drugs as “not covered,” an Express Scripts spokesman told FiercePharma, adding "Drug choices in some classes are larger than ever, with many products costing more with no additional health benefit."

The co-pay card, a marketing tactic often used by pharma to provide patient assistance for branded drugs, played into Express Scripts's decision, FiercePharma points out.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Penn and Teller give take on vaccines

The Las Vegas twosome give the anti-vaccination movement their signature treatment.

GSK allegations build in Jordan and Lebanon

GlaxoSmithKline says it is investigating allegations of employee misconduct. The company said in a statement that the allegations have numbers "very similar to those reported by other companies in our sector."

Generic Celebrex is coming

Pfizer and Teva's settlement puts generic Celebrex on the market by December.